Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov 10;13(11):1577.
doi: 10.3390/brainsci13111577.

A Systematic Review on the Effectiveness of Antipsychotic Drugs on the Quality of Life of Patients with Schizophrenia

Gaia Sampogna  1 , Matteo Di Vincenzo  1 , Luigi Giuliani  1 , Giulia Menculini  2 , Emiliana Mancuso  1 , Eleonora Arsenio  1 , Salvatore Cipolla  1 , Bianca Della Rocca  1 , Vassilis Martiadis  3 , Maria Salvina Signorelli  4 , Andrea Fiorillo  1
Affiliations
Review

A Systematic Review on the Effectiveness of Antipsychotic Drugs on the Quality of Life of Patients with Schizophrenia

Gaia Sampogna et al. Brain Sci. .

Abstract

Pharmacological antipsychotic drug interventions represent the cornerstone of the management of patients with schizophrenia and other psychotic spectrum disorders. The choice of the "best" treatment should be made on the basis of several clinical domains. However, despite available treatments, the quality of life reported by patients with schizophrenia taking antipsychotics is still very poor, and this outcome is rarely taken into account in trials assessing the efficacy and effectiveness of antipsychotic treatments. Therefore, we performed a systematic review in order to assess the impact of antipsychotic treatment on patients' quality of life. In particular, we aimed to identify any differences in the improvement in quality of life according to the (a) type of formulation of antipsychotic drugs (i.e., oral vs. depot vs. long-acting injectable); (b) type of the drug (first vs. second vs. third generation); and (c) patients' clinical characteristics. One hundred and eleven papers were included in the review. The main findings were as follows: (1) quality of life is usually considered a secondary outcome in trials on the efficacy and effectiveness of drugs; (2) second-generation antipsychotics have a more positive effect on quality of life; and (3) long-acting injectable antipsychotics are associated with a more stable improvement in quality of life and with a good safety and tolerability profile. Our systematic review confirms that quality of life represents a central element for selecting the appropriate treatment for people with schizophrenia. In particular, the availability of new treatments with a better tolerability profile, a proven effectiveness on patients' cognitive and social functioning, and with a more stable blood concentration might represent the appropriate strategy for improving the quality of life of people with schizophrenia.

Keywords: antipsychotic drugs; neuroleptics; outcome assessment; personalized treatment; quality of life; schizophrenia.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
PRISMA flowchart.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Charlson F.J., Ferrari A.J., Santomauro D.F., Diminic S., Stockings E., Scott J.G., McGrath J.J., Whiteford H.A. Global epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016. Schizophr. Bull. 2018;44:1195–1203. doi: 10.1093/schbul/sby058. - DOI - PMC - PubMed
    1. Stein D.J., Shoptaw S.J., Vigo D.V., Lund C., Cuijpers P., Bantjes J., Sartorius N., Maj M. Psychiatric diagnosis and treatment in the 21st century: Paradigm shifts versus incremental integration. World Psychiatry. 2022;21:393–414. doi: 10.1002/wps.20998. - DOI - PMC - PubMed
    1. Correll C.U., Solmi M., Croatto G., Schneider L.K., Rohani-Montez S.C., Fairley L., Smith N., Bitter I., Gorwood P., Taipale H., et al. Mortality in people with schizophrenia: A systematic review and meta-analysis of relative risk and aggravating or attenuating factors. World Psychiatry. 2022;21:248–271. doi: 10.1002/wps.20994. - DOI - PMC - PubMed
    1. Kiran C., Chaudhury S. Prevalence of comorbid anxiety disorders in schizophrenia. Ind. Psychiatry J. 2016;25:35–40. doi: 10.4103/0972-6748.196045. - DOI - PMC - PubMed
    1. Wang Q., Zhang L., Zhang J., Ye Z., Li P., Wang F., Cao Y., Zhang S., Zhou F., Ai Z., et al. Prevalence of Comorbid Personality Disorder in Psychotic and Non-psychotic Disorders. Front. Psychiatry. 2021;12:800047. doi: 10.3389/fpsyt.2021.800047. - DOI - PMC - PubMed

LinkOut - more resources